Total Payments
$900,598
2024 Payments
$278,689
Companies
3
Transactions
193
Payment Breakdown by Category
Consulting$900,376 (100.0%)
Food & Beverage$221.97 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $900,376 | 190 | 100.0% |
| Food and Beverage | $221.97 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Dynavax Technologies Corporation | $900,376 | 190 | $0 (2024) |
| Silk Road Medical, Inc. | $129.13 | 1 | $0 (2021) |
| ARBOR PHARMACEUTICALS, INC. | $92.84 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $278,689 | 51 | Dynavax Technologies Corporation ($278,689) |
| 2023 | $239,575 | 59 | Dynavax Technologies Corporation ($239,575) |
| 2021 | $144,854 | 13 | Dynavax Technologies Corporation ($144,725) |
| 2020 | $136,325 | 43 | Dynavax Technologies Corporation ($136,325) |
| 2019 | $90,475 | 21 | Dynavax Technologies Corporation ($90,475) |
| 2018 | $10,680 | 6 | Dynavax Technologies Corporation ($10,588) |
All Payment Transactions
193 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $15,574.99 | General |
| Category: Hepatitis B Vaccine | ||||||
| 12/19/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 12/19/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 12/19/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $350.01 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/21/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $23,275.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/21/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $8,400.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/21/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/21/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/21/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $16,275.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 09/20/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $18,200.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 09/20/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 09/20/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 09/20/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/23/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $23,975.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/23/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/23/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/23/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 07/26/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $17,675.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 07/26/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 07/26/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Hepatitis B Vaccine | ||||||
About Dr. Teck Ling, MD
Dr. Teck Ling, MD is a Internal Medicine healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1578725792.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Teck Ling, MD has received a total of $900,598 in payments from pharmaceutical and medical device companies, with $278,689 received in 2024. These payments were reported across 193 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($900,376).
Ad
Practice Information
- Specialty Internal Medicine
- Location Palo Alto, CA
- Active Since 06/29/2008
- Last Updated 06/29/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578725792
Products in Payments
- Heplisav-B (Drug) $900,376
- ENHANCE Transcarotid Peripheral Access Kit (Device) $129.13
- Horizant (Drug) $92.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Palo Alto
Jennie Crews
Internal Medicine — Payments: $486,491
Internal Medicine $486,491
Byron Lee, Md, MD
Internal Medicine — Payments: $330,042
Internal Medicine $330,042
Bita Fakhri, M.d., M.p.h, M.D., M.P.H
Internal Medicine — Payments: $151,916
Internal Medicine $151,916
Curtis Chong, Md, Phd, MD, PHD
Internal Medicine — Payments: $122,210
Internal Medicine $122,210
Dr. Richard Mamelok, M.d, M.D
Internal Medicine — Payments: $120,882
Internal Medicine $120,882
Millie Das, Md, MD
Internal Medicine — Payments: $105,357
Internal Medicine $105,357